|
Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer
WHIPPANY, N.J., April 20 /PRNewswire/ -- As part of a Research and
Development partnership between Halo Pharmaceutical and DeMelleBioPharma,
LLC, Dr. George Bobotas joins Halo Pharmaceutical as Chief Scientific
Officer. Halo and DeMelle are working closely together in this alliance on
the development of several client products. "I am excited at the potential
synergies between these two dynamic companies and the opportunity to work
closely together with a talented group of pharmaceutical professionals,"
said Dr. George Bobotas.
Dr. Bobotas has been President and Managing Partner of
DeMelleBioPharma, LLC since 2008. He was employed at Reliant
Pharmaceuticals (a wholly owned subsidiary of GlaxoSmithKline plc) for
eight years in the position of Vice President, Scientific Affairs. At
Reliant, he led teams for the development and commercialization of products
with combined marketing penetration of over US$1.00 Billion including
Lovaza and Antara among many others. Prior to Reliant, he was the founder
and Executive Director of the Covance Center for CNS Research. Earlier in
his career, Dr. Bobotas has held senior positions at Mylan Laboratories,
Somerset Pharmaceuticals and Forest Laboratories. He is the inventor of 24
patents and patent applications. Dr. Bobotas received his Ph.D. in
Biochemistry from the City University of New York. He has also received
graduate training in Industrial Pharmacy and Physical Chemistry. He is a
member of the American Association of Pharmaceutical Scientists, American
College of Clinical Pharmacology and American Society for Experimental
Neurotherapeutics.
"Having Dr. Bobotas on its team, Halo now has the capability to develop
more complicated products and provide services to its existing and future
clients with challenging technical transfers and new Product Development
opportunities. We are excited to have George on board," said Mohd Asif,
Chief Financial Officer of Halo Pharmaceutical.
Halo capabilities include an impressive array of formulation services,
Commercial operations for solid dosage forms, and operations for the
aseptic filling of topical ointments, solid dosage forms(tablets and
capsules), liquids, suppositories, associated packaging (tablet, powder,
liquids and HUD) and ample laboratory space for formulation development,
pre-clinical and clinical supplies and support of commercial operations. An
additional asset is the site's capability to manufacture controlled
substances (C2-C5) and an API manufacturing unit with an outstanding track
record of meeting DEA requirements.
About Halo Pharmaceutical
Halo Pharmaceutical, headquartered in Whippany, NJ, is a full-service,
specialty pharmaceutical company, offering state-of-the-art contract
manufacturing, early stage formulation development and laboratory services
to the pharmaceutical and related industries. Halo is currently a supplier
of choice to a number of large and medium size brand pharmaceutical
companies for important life cycle products. Contract manufacturing
capabilities include the ability to conduct aseptic filling, granulation,
blending, tableting, coating, packaging, and related warehousing
operations. Halo Pharmaceutical is a privately-held company.
About DeMelleBioPharma
DeMelle participates in new drug development through strategic
alliances across a broad range of pharmaceutical dosage forms and
therapeutic areas. The founders of DeMelle have a significant amount of
experience in the pharmaceutical industry. They were responsible in
bringing a number of novel drug products to commercialization.
|
